Amount of hepatic fat predicts cardiovascular risk independent of insulin resistance among Hispanic-American adolescents

Lipids in Health and Disease

Miriam B Vos¹  James Otvos⁵  Jessica Cruz Muños⁴  Xiaoyan Sun²  Rebecca Cleeton⁴  Ngoc-Anh Le³  Ran Jin⁴ 

[1] Children’s Healthcare of Atlanta, Atlanta, GA, USA;Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA;Biomarker Core Laboratory, Atlanta Veterans Affairs Medical Center, Decatur, GA, USA;Division of Pediatric Gastroenterology, Hepatology and Nutrition, School of Medicine, Emory University, Atlanta 30322, GA, USA;LipoScience Inc, Raleigh, NC, USA

关键词: Children and Adolescents;    Cardiovascular risk;    Lipoproteins;    Lipids;    Hepatic steatosis;    Non-alcoholic fatty liver disease;   

Others  :  1216062
DOI  :  10.1186/s12944-015-0038-x

 received in 2015-01-06, accepted in 2015-04-17,  发布年份 2015

【 摘 要 】

Background

Nonalcoholic fatty liver disease (NAFLD) has emerged as the major pediatric chronic liver disease, and it is estimated to affect more than one third of obese children in the U.S. Cardiovascular complications are a leading cause of increased mortality in adults with NAFLD and many adolescents with NAFLD already manifest signs of subclinical atherosclerosis including increased carotid intima-media thickness.

Methods

Volume of intrahepatic fat was assessed in 50 Hispanic-American, overweight adolescents, using Magnetic Resonance Spectroscopy. Lipoprotein compositions were measured using Nuclear Magnetic Resonance.

Results

Plasma triglycerides (TG) (p = 0.003), TG/HDL ratio (p = 0.006), TG/apoB ratio (p = 0.011), large VLDL concentration (p = 0.019), VLDL particle size (p = 0.012), as well as small dense LDL concentration (p = 0.026) progressively increased across higher levels of hepatic fat severity, while large HDL concentration progressively declined (p = 0.043). This pattern of associations remained even after controlling for gender, BMI, visceral fat, and insulin resistance.

Conclusions

Our findings suggest that increased hepatic fat is strongly associated with peripheral dyslipidemia and the amount of fat in the liver may influence cardiovascular risk. Further studies are needed to longitudinally monitor dyslipidemia in children with NAFLD and to examine whether the reduction of hepatic fat would attenuate their long-term CVD risk.

【 授权许可】

   
2015 Jin et al.; licensee BioMed Central.

【 参考文献 】

• [1]Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J et al.. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010; 52:913-24.
• [2]Pulgaron ER, Delamater AM. Obesity and type 2 diabetes in children: epidemiology and treatment. Curr Diab Rep. 2014; 14:508.
• [3]Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008; 28:13-24.
• [4]Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics. 2005; 115:e561-5.
• [5]Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R et al.. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med. 2006; 23:403-9.
• [6]Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol. 2005; 11:4838-42.
• [7]Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A et al.. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129:113-21.
• [8]Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T et al.. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009; 7:234-8.
• [9]Pacifico L, Cantisani V, Ricci P, Osborn JF, Schiavo E, Anania C et al.. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res. 2008; 63:423-7.
• [10]Demircioglu F, Kocyigit A, Arslan N, Cakmakci H, Hizli S, Sedat AT. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2008; 47:68-75.
• [11]Jin R, Le NA, Liu S, Farkas Epperson M, Ziegler TR, Welsh JA et al.. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab. 2012; 97:E1088-98.
• [12]Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008; 118:277-83.
• [13]Burns SF, Lee SJ, Arslanian SA. Surrogate lipid markers for small dense low-density lipoprotein particles in overweight youth. J Pediatr. 2012; 161:991-6.
• [14]Giannini C, Santoro N, Caprio S, Kim G, Lartaud D, Shaw M et al.. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care. 2011; 34:1869-74.
• [15]Toth PP. Insulin resistance, small LDL particles, and risk for atherosclerotic disease. Curr Vasc Pharmacol. 2014; 12:653-7.
• [16]Gentile M, Panico S, Mattiello A, Ubaldi S, Iannuzzo G, De Michele M et al.. Association between small dense LDL and early atherosclerosis in a sample of menopausal women. Clin Chim Acta. 2013; 426:1-5.
• [17]Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011; 43:617-49.
• [18]Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G et al.. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44:865-73.
• [19]Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363:1341-50.
• [20]Ciccone MM, Principi M, Ierardi E, Di Leo A, Ricci G, Carbonara S et al.. Inflammatory bowel disease, liver diseases and endothelial function: is there a linkage? J Cardiovasc Med (Hagerstown). 2015; 16:11-21.
• [21]Cali AM, Zern TL, Taksali SE, de Oliveira AM, Dufour S, Otvos JD et al.. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state. Diabetes Care. 2007; 30:3093-8.
• [22]DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K et al.. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2013; 227:429-36.
• [23]Burns SF, Lee S, Arslanian SA. In vivo insulin sensitivity and lipoprotein particle size and concentration in black and white children. Diabetes Care. 2009; 32:2087-93.
• [24]Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008; 134:424-31.
• [25]Jacome-Sosa MM, Parks EJ. Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans. Curr Opin Lipidol. 2014; 25:213-20.
• [26]Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014; 146:726-35.
• [27]Stanhope KL, Havel PJ. Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipidol. 2008; 19:16-24.
• [28]Adiels M, Taskinen MR, Boren J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep. 2008; 8:60-4.
• [29]Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol. 2006; 17:412-7.
• [30]Rizzo M, Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev. 2007; 23:14-20.
• [31]Nordestgaard BG. The vascular endothelial barrier–selective retention of lipoproteins. Curr Opin Lipidol. 1996; 7:269-73.
• [32]Freedman DS, Bowman BA, Otvos JD, Srinivasan SR, Berenson GS. Levels and correlates of LDL and VLDL particle sizes among children: the Bogalusa heart study. Atherosclerosis. 2000; 152:441-9.
• [33]Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014; 59:713-23.
• [34]Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab. 2012; 15:574-84.
• [35]Bieghs V, Rensen PC, Hofker MH, Shiri-Sverdlov R. NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis. 2012; 220:287-93.
• [36]Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol. 2014; 20:13306-24.
• [37]Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res. 2011; 42:337-53.
• [38]Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 2013; 5:928-48.
• [39]Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD et al.. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids. 2009; 44:9-16.
• [40]Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 2006; 113:2548-55.
• [41]Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003; 23:712-9.
• [42]Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K et al.. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011; 364:127-35.
• [43]D’Adamo E, Northrup V, Weiss R, Santoro N, Pierpont B, Savoye M et al.. Ethnic differences in lipoprotein subclasses in obese adolescents: importance of liver and intraabdominal fat accretion. Am J Clin Nutr. 2010; 92:500-8.
• [44]Nonomura K, Arai Y, Mitani H, Abe-Dohmae S, Yokoyama S. Insulin down-regulates specific activity of ATP-binding cassette transporter A1 for high density lipoprotein biogenesis through its specific phosphorylation. Atherosclerosis. 2011; 216:334-41.
• [45]Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging. 1994; 12:487-95.
• [46]Goran MI, Ventura EE. Genetic predisposition and increasing dietary fructose exposure: the perfect storm for fatty liver disease in Hispanics in the U.S. Dig Liver Dis. 2012; 44:711-3.
• [47]Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology. 2013; 57:2525-31.
• [48]Pineda N, Sharma P, Xu Q, Hu X, Vos M, Martin DR. Measurement of hepatic lipid: high-speed T2-corrected multiecho acquisition at 1H MR spectroscopy–a rapid and accurate technique. Radiology. 2009; 252:568-76.
• [49]Glover GH, Schneider E. Three-point Dixon technique for true water/fat decomposition with B0 inhomogeneity correction. Magn Reson Med. 1991; 18:371-83.
• [50]Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006; 26:847-70.
• [51]Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C et al.. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012; 55:1389-97.